Comments
Intas Pharmaceuticals informed that the company has launched Intacept - a biosimilar to Amgen's Enbrel (entanercept) in the strengths of 25mg in 0.5 ml and 50mg in 1.0 ml preservative free solution in pre-filled syringes.
Etanercept is indicated for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Plaque Psoriasis all debilitating autoimmune diseases, the company stated.
Commenting on the launch, Binish Chudgar, vice-chairman, Intas said, "Etanercept is a fusion protein that is difficult to develop. Intacept is a further validation of our world-class R&D and manufacturing capabilities that bring global healthcare standards to Indian patients at a lower cost. Through Intacept, we are able to reduce the cost of treatment for patients to about half of the imported Enbrel."
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.